Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024
Swiss pharmaceutical giant Novartis (NYSE: NVS) presented updated results from the pivotal Phase III NATALEE...
Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial
China-based Legend Biotech Corporation (NASDAQ: LEGN) has released new data on minimal residual disease (MRD)...
Huadong Medicine’s Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving another indication approval from the...
IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study
China-based IMEIK Technology Development Co., Ltd (SHE: 300896) has announced receiving approval from the National...
Patronus Biotech’s RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study
Guangzhou Patronus Biotech Co., Ltd., a vaccine start-up specializing in respiratory and infectious diseases, has...
Shanghai Pharmaceuticals’ SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment
China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced that the US Food and...
Sperogenix Therapeutics’ Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment
China-based rare disease specialist Sperogenix Therapeutics Limited has announced receiving marketing approval from the National...
Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy
The Beijing Municipal Medical Insurance Bureau has released a notification that significantly expands the scope...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Merck’s PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China
US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has announced receiving marketing approval from...
MSD’s Noxafil Receives NMPA Approval for Pediatric Use in Antifungal Treatment
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that China’s National Medical...
NMPA Approves Zynlonta for Relapsed or Refractory Large B-Cell Lymphoma Treatment
The website of China’s National Medical Products Administration (NMPA) has indicated that the marketing filing...
Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024
China-based Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced the presentation of results from...
Porton Pharma Solutions and OD Kingsley Life Sciences Form Partnership for Bio Conjugated Drug Development
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions (SHE: 300363) has announced a...
Stereotaxis and MicroPort EP Receive NMPA Approval for Magbot Magnetic Navigation Ablation Catheter
US-based Stereotaxis, Inc. (NYSEAMERICAN: STXS) and its Chinese partner Shanghai MicroPort EP Medtech Co., Ltd....
Immunofoco’s IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer
Immunofoco, a leading developer in tumor immunotherapy based in Suzhou, has announced that it has...
InnoVec Biotherapeutics’ IVB102 Receives FDA IND Approval for X-Linked Retinoschisis Treatment
Beijing-based gene therapy specialist InnoVec Biotherapeutics Inc. has announced receiving Investigational New Drug (IND) approval...
Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with...
Eisai’s Urece (Dotinurad) Approved by China’s NMPA for Gout Treatment with Hyperuricemia
Eisai’s (TYO: 4523) China unit has announced that it has received marketing approval from the...
Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation
Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced that their...